Esperion Therapeutics $250 million convertible senior subordinated notes
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Esperion Therapeutics, Inc. of $250 million aggregate principal amount of its 4.000% convertible senior subordinated notes due 2025. In addition, Davis Polk advised counterparties to capped call and prepaid forward transactions in connection with the offering.
Esperion Therapeutics, based in Ann Arbor, Michigan, is the Lipid Management Company, a pharmaceutical company focused on developing and commercializing affordable, oral, once-daily, non-statin medicines for the treatment of patients with elevated low-density lipoprotein cholesterol. The company’s common stock is listed on the Nasdaq Global Market under the symbol “ESPR.”
The Davis Polk corporate team included partner Richard D. Truesdell Jr. and associate Elliot de Carvalho. The equity derivatives team included partner John M. Brandow and associates Katharine O’Banion, Annie Li, Danielle Forni and Yini Chen. The tax team included partner Po Sit and associate Ben Levenback. Members of the Davis Polk team are based in the New York and São Paulo offices.